{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:08:57Z","timestamp":1785766137246,"version":"3.56.0"},"reference-count":34,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Understanding interindividual variability in treatment response and toxicity is essential for optimizing outcomes in pediatric acute lymphoblastic leukemia (ALL). Molecular and pharmacogenetic markers hold promise in predicting treatment efficacy and adverse effects, particularly in genetically diverse populations. This protocol outlines the methodology for a prospective, nonrandomized observational cohort designed to evaluate molecular and pharmacogenetic factors associated with treatment response and toxicity in Indian children diagnosed with ALL.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The primary objective is to identify genetic markers associated with treatment-related toxicity and therapeutic response. Secondary objectives include evaluating associations between the occurrence of early toxicities and quality of life during active ALL treatment, specific pharmacogenetic variants, and survival outcomes along with generating data to support the future implementation of personalized treatment strategies in Indian children with ALL.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In this prospective, observational cohort, 556 children (\u226418 years of age) with newly diagnosed ALL treated under the Indian Childhood Collaborative Leukemia\u2013Acute Lymphoblastic Leukemia 2014 (ICiCLe-ALL-14) protocol at two Indian centers will be enrolled, aiming for a minimum of 500 evaluable children. Eligible participants will be enrolled prior to the initiation of chemotherapy and followed longitudinally throughout treatment. Clinical and laboratory data (demographics, nutritional assessment, quality of life, comorbidities, treatment regimen, toxicity graded by Common Terminology Criteria for Adverse Events v5.0, remission status, and survival) will be collected at predefined intervals up to day 100 of the maintenance phase. Germline and somatic DNA will be sampled at diagnosis and remission. The first phase will use whole-exome sequencing to discover candidate variants by implementing a candidate gene prioritization strategy. The second phase will genotype the top candidates in the full cohort using array technology. Associations with early treatment\u2013related toxicities, steroid response, and survival will be tested by multivariable regression and Cox models. A machine learning approach with pharmacogenetic predictors as classifiers will be implemented further with cross-validation and sensitivity analyses.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Ethical committees approved the protocol version 1.0 in 2020: IEC-1167\/06.11.2020 (All India Institute of Medical Sciences, New Delhi), JIP\/IEC\/2020\/201 (Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry), and AO_2021-00048 (UNIGE, Geneva). Funding was received from Swiss National Science Foundation, Switzerland; Department of Biotechnology, India; and CANSEARCH Foundation, Switzerland. Recruitment began in December 2022 and is likely to conclude by 2027. A comprehensive analysis of the complete study cohort is anticipated to be completed by 2027.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The MPGx-INDALL (Molecular and Pharmacogenetic Marker Evaluation in Relation to the Toxicity and Clinical Response of Acute Lymphoblastic Leukemia Treatment in Indian Children) study will generate actionable insights for individualized ALL therapy in India via systematically evaluating germline and somatic markers in a large ethnically distinct cohort.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/79865","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T09:00:07Z","timestamp":1766566807000},"page":"e79865-e79865","source":"Crossref","is-referenced-by-count":1,"title":["Molecular and Pharmacogenetic Marker Evaluation in Relation to the Toxicity and Clinical Response of Acute Lymphoblastic Leukemia Treatment in Indian Children (MPGx-INDALL): Protocol for a Prospective Observational Cohort Study"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3484-4485","authenticated-orcid":false,"given":"Swetambri","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7296-6088","authenticated-orcid":false,"given":"Shuvadeep","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6770-8340","authenticated-orcid":false,"given":"Kamali","family":"Murugadoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-7377","authenticated-orcid":false,"given":"Smita","family":"Kayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2834-3868","authenticated-orcid":false,"given":"Swaminathan","family":"Keerthivasagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaikumar","family":"Ramamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6487-6632","authenticated-orcid":false,"given":"Archna","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8222-331X","authenticated-orcid":false,"given":"Deepam","family":"Pushpam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2339-0262","authenticated-orcid":false,"given":"Jayanthi","family":"Mathaiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8790-0479","authenticated-orcid":false,"given":"Yvonne","family":"Gloor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8059-3015","authenticated-orcid":false,"given":"Frederic","family":"Baleydier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9649-6498","authenticated-orcid":false,"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-4407","authenticated-orcid":false,"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9852-2525","authenticated-orcid":false,"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8928-7049","authenticated-orcid":false,"given":"Chakradhara Rao S","family":"Uppugunduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"2","key":"R1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"R2","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group","volume":"30","author":"Hunger","journal-title":"J Clin Oncol"},{"issue":"5","key":"R3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2141.2005.05773.x","article-title":"Childhood acute lymphoblastic leukaemia and relapse","volume":"131","author":"Gaynon","journal-title":"Br J Haematol"},{"issue":"4","key":"R4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41588-021-00819-w","article-title":"A first-generation pediatric cancer dependency map","volume":"53","author":"Dharia","journal-title":"Nat Genet"},{"issue":"6","key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26327","article-title":"High hyperdiploid acute lymphoblastic leukemia (ALL)\u2014a 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-M\u00fcnster) Study Group","volume":"64","author":"Reism\u00fcller","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phoj.2018.11.052","article-title":"Implementation of risk adapted therapeutic strategy for childhood acute lymphoblastic leukaemia\u2014interim report of the pilot InPOG-ALL-15-01 study","volume":"3","author":"Roy","journal-title":"Pediatric Hematology Oncology Journal"},{"issue":"1","key":"R7","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06033-1","article-title":"Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India","volume":"23","author":"Das","journal-title":"Trials"},{"issue":"27","key":"R8","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","journal-title":"J Clin Oncol"},{"issue":"9617","key":"R9","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","journal-title":"The Lancet"},{"issue":"9","key":"R10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/gcc.20684","article-title":"Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome","volume":"48","author":"Karrman","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"R11","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000782","article-title":"Clinical and prognostic impact of copy number alterations and associated risk profiles in a cohort of pediatric B-cell precursor acute lymphoblastic leukemia cases treated under ICiCLe protocol","volume":"6","author":"Gupta","journal-title":"Hemasphere"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2025.100593","article-title":"Risk stratified treatment for childhood acute lymphoblastic leukaemia: a multicentre observational study from India","volume":"37","author":"Gogoi","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"2","key":"R13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4103\/CRST.CRST_85_20","article-title":"Outcomes and impact of minimal residual disease (MRD) in pediatric, adolescent and young adults (AYA) with acute lymphoblastic leukemia treated with modified MCP 841 protocol","volume":"3","author":"Pandey","journal-title":"Cancer Res Stat Treat"},{"issue":"6","key":"R14","doi-asserted-by":"publisher","DOI":"10.3390\/genes11060594","article-title":"Association of NUDT15*3 and FPGS 2572C>T variants with the risk of early hematologic toxicity during 6-MP and low-dose methotrexate-based maintenance therapy in Indian patients with acute lymphoblastic leukemia","volume":"11","author":"Kodidela","journal-title":"Genes (Basel)"},{"issue":"Supplement_1","key":"R15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127091","article-title":"Outcomes in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL): a report from the Indian acute leukemia research database (INwARD) of the hematology cancer consortium (HCC)","volume":"134","author":"Ganesan","journal-title":"Blood"},{"issue":"3","key":"R16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.phoj.2018.11.004","article-title":"Exploring barriers to accessing care for childhood cancers In India: a qualitative study (Inpog-Acc-16-03)","volume":"3","author":"Faruqui","journal-title":"Pediatr Hematol Oncol J"},{"issue":"6","key":"R17","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1359","article-title":"Patient tracking during treatment of children with cancer in India\u2014an exploratory study","volume":"5","author":"Ahuja","journal-title":"Cancer Rep"},{"issue":"5","key":"R18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/MPH.0b013e3181d7ae0d","article-title":"Pattern of relapse in childhood ALL: challenges and lessons from a uniform treatment protocol","volume":"32","author":"Arya","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"R19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00280-018-3732-3","article-title":"Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia","volume":"83","author":"Khera","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"R20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002200","article-title":"IL-7 receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: a genome sequencing study","volume":"13","author":"Li","journal-title":"PLoS Med"},{"issue":"4","key":"R21","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/oxfordjournals.bmb.a011577","article-title":"Geographic and ethnic variations in the incidence of childhood cancer","volume":"52","author":"Stiller","journal-title":"Br Med Bull"},{"issue":"4","key":"R22","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/cts.13153","article-title":"Pharmacogenomic landscape of Indian population using whole genomes","volume":"15","author":"Sahana","journal-title":"Clin Transl Sci"},{"issue":"1","key":"R23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18231\/j.ijfcm.2021.001","article-title":"Modified Kuppuswamy socioeconomic scale updated for the year 2021","volume":"8","author":"Saleem","journal-title":"Indian J Forensic Community Med"},{"key":"R24","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE): Version 5.0. US Department of Health and Human Services; Nov 27, 2017. URL: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf [Accessed 04-02-2026]"},{"issue":"7","key":"R25","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1002\/cncr.10428","article-title":"The PedsQL in pediatric cancer: reliability and validity of the pediatric quality of life inventory generic core scales, multidimensional fatigue scale, and cancer module","volume":"94","author":"Varni","journal-title":"Cancer"},{"issue":"7263","key":"R26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature08365","article-title":"Reconstructing Indian population history","volume":"461","author":"Reich","journal-title":"Nature"},{"issue":"7319","key":"R27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature09534","article-title":"A map of human genome variation from population-scale sequencing","volume":"467","author":"The 1000 Genomes Project Consortium","journal-title":"Nature New Biol"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1186\/s13742-015-0047-8","article-title":"Second-generation PLINK: rising to the challenge of larger and richer datasets","volume":"4","author":"Chang","journal-title":"Gigascience"},{"issue":"1","key":"R29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1467-9868.2004.00439.x","article-title":"Strong control, conservative point estimation and simultaneous conservative consistency of false discovery rates: a unified approach","volume":"66","author":"Storey","journal-title":"J R Stat Soc B"},{"key":"R30","unstructured":"R Project. URL: https:\/\/www.r-project.org\/ [Accessed 09-02-2026]"},{"issue":"4","key":"R31","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1086\/319501","article-title":"A new statistical method for haplotype reconstruction from population data","volume":"68","author":"Stephens","journal-title":"Am J Hum Genet"},{"issue":"2","key":"R32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ygeno.2010.11.003","article-title":"On the use of multifactor dimensionality reduction (MDR) and classification and regression tree (CART) to identify haplotype-haplotype interactions in genetic studies","volume":"97","author":"Hsieh","journal-title":"Genomics"},{"issue":"3","key":"R33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00122-012-1892-9","article-title":"Overview of LASSO-related penalized regression methods for quantitative trait mapping and genomic selection","volume":"125","author":"Li","journal-title":"Theor Appl Genet"},{"issue":"2","key":"R34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ng1706","article-title":"Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies","volume":"38","author":"Skol","journal-title":"Nat Genet"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e79865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:13:04Z","timestamp":1782843184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e79865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":34,"URL":"https:\/\/doi.org\/10.2196\/79865","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"article-number":"v15i2e79865"}}